Bulevirtide
•Anti-viral
•First ever drug again hepatitis B
•Without cirrhosis
•“Entry inhibitor". It blocks hepatitis D virus entering healthy liver cells
•Anti-viral
•First ever drug again hepatitis B
•Without cirrhosis
•“Entry inhibitor". It blocks hepatitis D virus entering healthy liver cells
September 1, 2026 at 2:31 PM
Bulevirtide
•Anti-viral
•First ever drug again hepatitis B
•Without cirrhosis
•“Entry inhibitor". It blocks hepatitis D virus entering healthy liver cells
•Anti-viral
•First ever drug again hepatitis B
•Without cirrhosis
•“Entry inhibitor". It blocks hepatitis D virus entering healthy liver cells
@EASLedu @EASLedu @HeinerWedemeyer #bulevirtide (BLV) @ 2mg sc QD x 48 wks leads to 45% response (undect. RNA or 2 log drop with nl ALT). LSM ⬇️. ⬆️bile salts due to NTCP blocade. No SAEs but slightly more itching. Planned for 144 wks. @US_FDA currently vetting. #ILC2022
December 3, 2024 at 1:03 AM
@EASLedu @EASLedu @HeinerWedemeyer #bulevirtide (BLV) @ 2mg sc QD x 48 wks leads to 45% response (undect. RNA or 2 log drop with nl ALT). LSM ⬇️. ⬆️bile salts due to NTCP blocade. No SAEs but slightly more itching. Planned for 144 wks. @US_FDA currently vetting. #ILC2022
The $GILD statement mentions there were no new concerns raised by @US_FDA regarding the safety and efficacy of #bulevirtide which already received conditional marketing authorization by @EMA_News in July 2020 under the brand name #Hepcludex
December 2, 2024 at 10:59 PM
The $GILD statement mentions there were no new concerns raised by @US_FDA regarding the safety and efficacy of #bulevirtide which already received conditional marketing authorization by @EMA_News in July 2020 under the brand name #Hepcludex
Error
www.gilead.com
December 2, 2024 at 10:54 PM
The first approval for a drug to treat #HDV in the US will have to wait. Apparently @US_FDA cited concerns over manufacturing and delivery of #Bulevirtide in its Complete Response Letter to $GILD...
December 2, 2024 at 10:49 PM
The first approval for a drug to treat #HDV in the US will have to wait. Apparently @US_FDA cited concerns over manufacturing and delivery of #Bulevirtide in its Complete Response Letter to $GILD...
𝑯𝒂𝒑𝒑𝒚 𝑭𝒓𝒊𝒅𝒂𝒚 𝒘𝒊𝒕𝒉 𝒕𝒉𝒆 𝑯𝒊𝒈𝒉𝒍𝒊𝒈𝒉𝒕𝒔 𝒐𝒇 𝒕𝒉𝒆 𝑾𝒆𝒆𝒌!
UKHD: bit.ly/43AvV02
VERAXA: bit.ly/4u25ZVU
Prizes & more: bit.ly/4wRADUF
UKHD: bit.ly/43AvV02
VERAXA: bit.ly/4u25ZVU
Prizes & more: bit.ly/4wRADUF
May 29, 2026 at 12:03 PM
𝑯𝒂𝒑𝒑𝒚 𝑭𝒓𝒊𝒅𝒂𝒚 𝒘𝒊𝒕𝒉 𝒕𝒉𝒆 𝑯𝒊𝒈𝒉𝒍𝒊𝒈𝒉𝒕𝒔 𝒐𝒇 𝒕𝒉𝒆 𝑾𝒆𝒆𝒌!
UKHD: bit.ly/43AvV02
VERAXA: bit.ly/4u25ZVU
Prizes & more: bit.ly/4wRADUF
UKHD: bit.ly/43AvV02
VERAXA: bit.ly/4u25ZVU
Prizes & more: bit.ly/4wRADUF
Let's begin the #VallHebronTalks by #VHIR with Stephan Urbe (German Center for Infection Research, DZIF): 'Discovery and development of Bulevirtide'
💻 Follow it online: https://gencat.zoom.us/j/85247866153
💻 Follow it online: https://gencat.zoom.us/j/85247866153
April 8, 2025 at 1:01 PM
Let's begin the #VallHebronTalks by #VHIR with Stephan Urbe (German Center for Infection Research, DZIF): 'Discovery and development of Bulevirtide'
💻 Follow it online: https://gencat.zoom.us/j/85247866153
💻 Follow it online: https://gencat.zoom.us/j/85247866153
Stephan Urbe (German Center for Infection Research, DZIF), will talk about the discovery and development of Bulevirtide for the treatment of Hepatitis B and D at the next #VallHebronTalks by #VHIR.
🗓️ 8th April - 3 p.m.
📍 Vall d'Hebron General Hospital
🔗 More: https://vallhebron.social/talks-urban
🗓️ 8th April - 3 p.m.
📍 Vall d'Hebron General Hospital
🔗 More: https://vallhebron.social/talks-urban
April 4, 2025 at 8:01 AM
Stephan Urbe (German Center for Infection Research, DZIF), will talk about the discovery and development of Bulevirtide for the treatment of Hepatitis B and D at the next #VallHebronTalks by #VHIR.
🗓️ 8th April - 3 p.m.
📍 Vall d'Hebron General Hospital
🔗 More: https://vallhebron.social/talks-urban
🗓️ 8th April - 3 p.m.
📍 Vall d'Hebron General Hospital
🔗 More: https://vallhebron.social/talks-urban
Bulevirtide (CAS: 1802008-27-5) – Purity 99.16% | GMP Factory
Bulevirtide (Myrcludex B) is a 47-amino acid NTCP inhibitor peptide that blocks HBV/HDV entry into liver cells. Manufactured in a GMP-certified facility with ≥99.16% purity. For research use only.（For wholesale prices, other…
Bulevirtide (Myrcludex B) is a 47-amino acid NTCP inhibitor peptide that blocks HBV/HDV entry into liver cells. Manufactured in a GMP-certified facility with ≥99.16% purity. For research use only.（For wholesale prices, other…
Bulevirtide (CAS: 1802008-27-5) – Purity 99.16% | GMP Factory
Bulevirtide (Myrcludex B) is a 47-amino acid NTCP inhibitor peptide that blocks HBV/HDV entry into liver cells. Manufactured in a GMP-certified facility with ≥99.16% purity. For research use only.（For wholesale prices, other specifications and uses, please consult our staff）
arizona-mall.com
August 6, 2025 at 1:29 PM
Bulevirtide (CAS: 1802008-27-5) – Purity 99.16% | GMP Factory
Bulevirtide (Myrcludex B) is a 47-amino acid NTCP inhibitor peptide that blocks HBV/HDV entry into liver cells. Manufactured in a GMP-certified facility with ≥99.16% purity. For research use only.（For wholesale prices, other…
Bulevirtide (Myrcludex B) is a 47-amino acid NTCP inhibitor peptide that blocks HBV/HDV entry into liver cells. Manufactured in a GMP-certified facility with ≥99.16% purity. For research use only.（For wholesale prices, other…
Hepatitis D: When the immune system gets out of control
Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effec...
weiterlesen
Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effec...
weiterlesen
February 6, 2025 at 10:42 AM
Hepatitis D: When the immune system gets out of control
Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effec...
weiterlesen
Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effec...
weiterlesen
#CROI2026 #idsky Efficacy & Safety of Bulevirtide (BLV) 2 or 10 mg in Chronic Hepatitis Delta (CHD) Including Patients With HIV/HBV: MYR301 Final Results presented by David Wyles. Long term BLV monotherapy for CHD for upto144wks was safe/effective (higher rates of undetectable virus w/10mg dose. 1/
February 26, 2026 at 12:59 AM
👏Congratulations! I wrote a review of HDV a just few years ago when Bulevirtide was being studied. Very important work—HDV is under appreciated and devastating
December 7, 2024 at 3:13 PM
👏Congratulations! I wrote a review of HDV a just few years ago when Bulevirtide was being studied. Very important work—HDV is under appreciated and devastating
Bulevirtide emerges as the only approved therapy for chronic hepatitis D, effectively reducing complications in patients with cirrhosis.
by Lampertico P, Anolli MP, Roulot D and Wedemeyer H in Gut #MedSky
📖 read the article: https://gut.bmj.com/content/early/2024/12/24/gutjnl-2024-332597
by Lampertico P, Anolli MP, Roulot D and Wedemeyer H in Gut #MedSky
📖 read the article: https://gut.bmj.com/content/early/2024/12/24/gutjnl-2024-332597
January 3, 2025 at 2:56 AM
Bulevirtide emerges as the only approved therapy for chronic hepatitis D, effectively reducing complications in patients with cirrhosis.
by Lampertico P, Anolli MP, Roulot D and Wedemeyer H in Gut #MedSky
📖 read the article: https://gut.bmj.com/content/early/2024/12/24/gutjnl-2024-332597
by Lampertico P, Anolli MP, Roulot D and Wedemeyer H in Gut #MedSky
📖 read the article: https://gut.bmj.com/content/early/2024/12/24/gutjnl-2024-332597
FDA approves Hepcludex for chronic hepatitis delta virus infection
https://cancerletter.com/drugs-and-targets/20260529_8b/
https://cancerletter.com/drugs-and-targets/20260529_8b/
FDA approves Hepcludex for chronic hepatitis delta virus infection - The Cancer Letter
FDA has approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. Hepcludex is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis, liver cancer, liver failure, and even death. To access this subscriber-only […]
cancerletter.com
June 1, 2026 at 7:00 PM
FDA approves Hepcludex for chronic hepatitis delta virus infection
https://cancerletter.com/drugs-and-targets/20260529_8b/
https://cancerletter.com/drugs-and-targets/20260529_8b/
FDA OKs First Treatment for Chronic Hepatitis D Infection https://www.medpagetoday.com/infectiousdisease/hepatitis/121433?
FDA OKs First Treatment for Chronic Hepatitis D Infection
In phase III study, patients taking bulevirtide had ALT normalization and steep drops in HDV RNA
www.medpagetoday.com
May 27, 2026 at 4:05 PM
FDA OKs First Treatment for Chronic Hepatitis D Infection https://www.medpagetoday.com/infectiousdisease/hepatitis/121433?
🌍 On #WorldHepatitisDay, discover how our @viromarkers.bsky.social project is advancing markers to predict which patients will respond best to new #HepatitisD drug #bulevirtide.
👉 europa.eu/!FfGjJN
#hepatitis #IHITransformingHealth #HorizonEU
👉 europa.eu/!FfGjJN
#hepatitis #IHITransformingHealth #HorizonEU
VIROMARKERS aims for revolution in care of people with persistent viral infections
The new project is advancing biomarkers that would improve the care of people living with HIV and hepatitis D, plus stem cell transplant patients at risk of cytomegalovirus (CMV).
europa.eu
July 28, 2025 at 9:37 AM
🌍 On #WorldHepatitisDay, discover how our @viromarkers.bsky.social project is advancing markers to predict which patients will respond best to new #HepatitisD drug #bulevirtide.
👉 europa.eu/!FfGjJN
#hepatitis #IHITransformingHealth #HorizonEU
👉 europa.eu/!FfGjJN
#hepatitis #IHITransformingHealth #HorizonEU
Big shift for HDV care: more reflex screening and hepatology pathways, not a blockbuster launch. Tip: prepare payer-ready referral + monitoring workflows for bulevirtide (Hepcludex) to capture eligible HBV patients. Full breakdown → https://future.xsbrt.com/HDVTreatmentFuture
Replies welcome
Replies welcome
May 24, 2026 at 12:00 AM
Big shift for HDV care: more reflex screening and hepatology pathways, not a blockbuster launch. Tip: prepare payer-ready referral + monitoring workflows for bulevirtide (Hepcludex) to capture eligible HBV patients. Full breakdown → https://future.xsbrt.com/HDVTreatmentFuture
Replies welcome
Replies welcome
Sechs Jahre nach Europa ließ die FDA die erste Therapie für Hepatitis Delta zu. 12 Millionen Menschen hatten bis Mai 2026 in den USA keine zugelassene Behandlung.
FDA lässt erste Therapie gegen Hepatitis Delta zu
Am 22. Mai 2026 erteilte die FDA Hepcludex (Bulevirtide) die erste US-Zulassung für chronische Hepatitis-Delta-Infektion. Rund 12 Millionen Menschen weltweit haben keine andere Behandlungsoption gehabt. Für Europa galt die Zulassung bereits seit 2020
denkstrom.org
July 22, 2026 at 3:31 AM
Sechs Jahre nach Europa ließ die FDA die erste Therapie für Hepatitis Delta zu. 12 Millionen Menschen hatten bis Mai 2026 in den USA keine zugelassene Behandlung.
Great news! The FDA approved the first treatment for hepatitis delta virus (HDV), a liver disease. This is a big step for folks at risk of liver failure.
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approv
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults suffering from chronic hepatitis delta virus (HDV) infection. This marks the fir
www.biospace.com
May 25, 2026 at 8:02 AM
Great news! The FDA approved the first treatment for hepatitis delta virus (HDV), a liver disease. This is a big step for folks at risk of liver failure.
Neglect of #HDV #HepatitisDelta in #clinicaltrials described in a poster - especially important as #bulevirtide arrives on the scene, but access and insights limited by inequity and data gaps. This work led by @mariondelphin.bsky.social
March 22, 2025 at 8:25 PM
Neglect of #HDV #HepatitisDelta in #clinicaltrials described in a poster - especially important as #bulevirtide arrives on the scene, but access and insights limited by inequity and data gaps. This work led by @mariondelphin.bsky.social
Neglect of #HDV #HepatitisDelta in #clinicaltrials described in a poster - especially important as #bulevirtide arrives on the scene, but access and insights are limited by inequity and data gaps.
This work led by @mariondelphin.bsky.social
This work led by @mariondelphin.bsky.social
March 22, 2025 at 8:12 PM
Neglect of #HDV #HepatitisDelta in #clinicaltrials described in a poster - especially important as #bulevirtide arrives on the scene, but access and insights are limited by inequity and data gaps.
This work led by @mariondelphin.bsky.social
This work led by @mariondelphin.bsky.social
Bulevirtide research in #VIROMARKERS: tracking hepatitis D biomarkers 🧬 #IHI #HorizonEurope #HealthcareInnovation #MedicalResearch #ResearchAndInnovation #HIV #HDV #CMV
@francinca.bsky.social @tyty4net.bsky.social @ihieurope.bsky.social
@francinca.bsky.social @tyty4net.bsky.social @ihieurope.bsky.social
March 11, 2026 at 7:54 AM
Bulevirtide research in #VIROMARKERS: tracking hepatitis D biomarkers 🧬 #IHI #HorizonEurope #HealthcareInnovation #MedicalResearch #ResearchAndInnovation #HIV #HDV #CMV
@francinca.bsky.social @tyty4net.bsky.social @ihieurope.bsky.social
@francinca.bsky.social @tyty4net.bsky.social @ihieurope.bsky.social
Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta www.tandfonline.com/doi/full/10.... #hvhebron #hepato
www.tandfonline.com
October 30, 2025 at 3:36 PM
Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta www.tandfonline.com/doi/full/10.... #hvhebron #hepato
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide
scientiasalut.gencat.cat
July 10, 2025 at 11:23 AM
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D
scientiasalut.gencat.cat
March 12, 2025 at 8:43 AM
Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D scientiasalut.gencat.cat/handle/11351... #ScientiaVH